Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Study Identifier:
ALXN1210-PNH-304
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: Ravulizumab
Date
Feb 2018 - Mar 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 17 Years
Requirements Information
Sex
Female & Male
Age
N/A - 17 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: Ravulizumab
Date
Feb 2018 - Mar 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 17 Years years
Requirements Information

Protocol Summary

The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).

Trial Locations

Location
Status
Location
Clinical Trial Site
Atlanta, Georgia, United States, 30329
Status
N/A
Location
Clinical Trial Site
Milwaukee, Wisconsin, United States, 53226
Status
N/A
Location
Clinical Trial Site
Paris, France
Status
N/A
Location
Clinical Trial Site
Utrecht, Netherlands
Status
N/A
Location
Clinical Trial Site
Oslo, Norway
Status
N/A
Location
Clinical Trial Site
Moscow, Russian Federation
Status
N/A